Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRISPR Therapeutics
Biotech
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
CRISPR Tx reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310.
Nick Paul Taylor
May 7, 2025 10:00am
Yet another exec departs CRISPR Tx—Chutes & Ladders
Mar 28, 2025 8:30am
RFK Jr. will divest interests in biotechs if HHS role confirmed
Jan 22, 2025 1:37pm
How 'remarkable' results in lupus carried CAR-T to immunology
May 30, 2024 9:00am
CRISPR Tx, Novartis, Cour & more—Chutes & Ladders
May 24, 2024 8:30am
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Feb 9, 2024 9:30am
